Please assess the completion status of the following clinical trial:

Trial Title: Risk of Nocturnal Hypoglycemia and Arrhythmias With Sitagliptin Versus Glimepiride in Patients With Type 2 Diabetes

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* type 2 diabetes~* age 40-80 years~* stable dose of ≥ 1500 mg metformin or maximal tolerated dose of metformin for \> 6 weeks~* HbA1c ≥ 7 % - ≤ 9.0% for age \< 65 years and ≥ 7.5 % - ≤ 9.0% for age ≥ 65 years~* able and trained to perform SMBG~* the informed consent form must be signed before any study specific tests or procedures are done~* ability to understand and follow study-related instructions~Exclusion Criteria:~* Type 1 diabetes~* previous treatment with insulin, GLP1 analogues and SU in \< 6 month~* HbA1c \> 9 % or FPG \> 15 mmol/l at randomization~* renal impairment with eGFR \< 60 ml/min~* medical history of severe hypoglycemia defined as necessity of medical assistance in \< 1 year~* major cardiovascular event (MACE) in medical history \< 6 months~* preexisting atrial fibrillation, , AV block ≥II degree, pace-maker, implanted defibrillator~* major cardiovascular event in medical history \< 6 months~* heart failure NYHA ≥ III~* contraindications to glimepiride and sitagliptin or to any excipients according to product information~* severe cognitive deficits~* Patients who are disable to read and understand informative aspects of the trial~* Subject currently is enrolled in or has not yet completed at least 30 days since ending other investigational device or drug study(s)~* Inability to comply with study procedures~* Pregnant or breast-feeding woman and woman without adequate method of contraception

- Gender: ALL
- Minimum Age: 40 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- Arm A (Type: EXPERIMENTAL): Patients receiving Sitagliptin 100 mg+ Glimepiride-placebo (adapted dosage)
- Arm B (Type: ACTIVE_COMPARATOR): Glimepiride (adapted dosage) + Sitagliptin 100 mg Placebo

Based on this trial design, predict the completion outcome and termination type (if applicable).